Literature DB >> 25820041

From 'Make in India' to 'Made in India': the saroglitazar story.

Sivasubramanian Ramakrishnan1.   

Abstract

Keywords:  Indian pharmaceutical industry; Made in India; PPAR agonists; Saroglitazar

Mesh：

Year:  2015        PMID： 25820041      PMCID： PMC4382552          DOI： 10.1016/j.ihj.2015.02.014

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


× No keyword cloud information.
  13 in total

1.  Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.

Authors:  Salim Yusuf; Prem Pais; Alben Sigamani; Denis Xavier; Rizwan Afzal; Peggy Gao; Koon K Teo
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-07-10

Review 2.  The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.

Authors:  P C Manoria; H K Chopra; S K Parashar; A L Dutta; Brian Pinto; Ajit Mullasari; Samir Prajapati
Journal:  Indian Heart J       Date:  2013-11-25

3.  Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.

Authors:  Sadanand R Shetty; Soumitra Kumar; R P Mathur; Kamal H Sharma; Ashok D Jaiswal
Journal:  Indian Heart J       Date:  2015-02-26

4.  The first approved agent in the Glitazar's Class: Saroglitazar.

Authors:  Ritesh Agrawal
Journal:  Curr Drug Targets       Date:  2014-02       Impact factor: 3.465

Review 5.  Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk.

Authors:  John S Millar
Journal:  Curr Opin Lipidol       Date:  2013-06       Impact factor: 4.776

6.  A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).

Authors:  Rajendrakumar H Jani; Vikas Pai; Pramod Jha; Gunjan Jariwala; Satinath Mukhopadhyay; Anil Bhansali; Shashank Joshi
Journal:  Diabetes Technol Ther       Date:  2013-10-18       Impact factor: 6.118

7.  Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Grennady Wirjanata; Boni Sebayang; Kim A Piera; Sergio Wittlin; Richard K Haynes; Jörg J Möhrle; Nicholas M Anstey; Enny Kenangalem; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

8.  Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

Authors:  Rajendra H Jani; Kevinkumar Kansagra; Mukul R Jain; Harilal Patel
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

9.  A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).

Authors:  Vikas Pai; A Paneerselvam; Satinath Mukhopadhyay; Anil Bhansali; Dinesh Kamath; V Shankar; Dhiraj Gambhire; Rajendrakumar H Jani; Shashank Joshi; Pankaj Patel
Journal:  J Diabetes Sci Technol       Date:  2014-01-16

Review 10.  Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review.

Authors:  Limei Wang; Birgit Waltenberger; Eva-Maria Pferschy-Wenzig; Martina Blunder; Xin Liu; Clemens Malainer; Tina Blazevic; Stefan Schwaiger; Judith M Rollinger; Elke H Heiss; Daniela Schuster; Brigitte Kopp; Rudolf Bauer; Hermann Stuppner; Verena M Dirsch; Atanas G Atanasov
Journal:  Biochem Pharmacol       Date:  2014-07-30       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.